Stock AnalizHeartflow, Inc. HTFL
Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026
Heartflow, Inc. (HTFL) is a healthcare company listed in the US with a market value of about $4.3B. In the twelve months to September 30, 2026 it had revenue of $239M and net income of -$79M, a net margin of -33.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 72.3, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $239M | $176M | $126M | $87M |
| Net income | -$79M | -$117M | -$96M | -$96M |
| Free cash flow | -$56M | -$59M | -$73M | -$83M |
| EPS (diluted) | $0.67 | $-3.17 | $-17.98 | $-25.32 |
| Net margin | -33.1% | -66.3% | -76.6% | -109.7% |
| ROIC | — | -19.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $63.12, 30% above the current price; targets range from $44.00 to $70.00; the consensus rating is “Strong buy”; expected EPS is $-0.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Heartflow’s P/E ratio?
About 72.3, based on the last twelve months of diluted earnings per share.
Is Heartflow stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Heartflow pay a dividend?
Not currently.
Is Heartflow a good stock to buy?
We do not give buy or sell advice. Heartflow scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.